immun
effect
method
reemerg
sar
recent
develop
sar
vaccin
shown
effect
anim
model
clinic
trial
howev
owe
low
incid
sar
infect
sinc
could
costli
vaccin
larg
suscept
popul
reason
rapid
costeffect
altern
circumst
could
implement
passiv
immunotherapi
human
neutral
monoclon
antibodi
mab
would
play
key
role
prevent
treatment
neutral
mab
demonstr
efficaci
prophylaxi
varieti
viral
infect
current
neutral
mab
sar
test
anim
model
proven
effect
protect
sarscoronaviru
cov
infect
made
possibl
use
passiv
transfer
neutral
mab
prevent
quick
spread
sarscov
case
region
outbreak
howev
key
task
involv
understand
underli
mechan
action
use
human
immunoglobulin
transgen
mous
coughlin
et
al
previous
produc
seri
neutral
human
mab
protein
sarscov
bound
epitop
within
upstream
residu
receptorbind
domain
rbd
present
studi
author
focus
understand
antivir
mechan
mab
accomplish
first
develop
receptor
bind
inhibit
assay
vero
cell
natur
express
receptor
angiotensinconvert
enzym
ace
detect
inhibit
mab
viral
attach
previous
identifi
mab
preincub
purifi
protein
express
sarscov
fuse
fc
human
igg
ad
vero
cell
detect
protein
bind
presenc
mab
target
cell
surfac
via
flow
cytometri
perform
result
demonstr
mab
design
group
recogn
seven
distinct
epitop
within
rbd
capabl
effici
inhibit
protein
bind
find
suggest
mechan
group
mab
might
involv
inhibit
sarscov
infect
block
viral
attach
cellular
receptor
target
cell
thu
appear
possess
receptorblock
mechan
similar
mab
previous
report
rockx
et
al
sui
et
al
respect
mab
recogn
partial
overlap
epitop
coincid
rbd
bind
conform
sensit
fragment
residu
overlap
rbd
author
demonstr
combin
mab
target
distinct
epitop
may
greatli
increas
inhibit
viru
infect
suppress
gener
neutral
escap
mutant
inhibit
human
mab
sarscoronaviru
cov
may
also
act
differ
mechan
action
depend
target
epitop
region
therefor
approach
could
provid
fast
effect
prophylaxi
treatment
sarscov
infect
sar
outbreak
specif
coughlin
et
al
indic
test
mab
recogn
epitop
within
receptorbind
domain
block
viru
attach
cellular
receptor
find
could
provid
step
understand
mechan
mab
prevent
sarscov
infect
well
insight
design
develop
novel
therapeut
treatment
reprint
order
pleas
contact
reprint
futuremedicinecom
futur
scienc
group
sinc
one
mab
fail
block
bind
protein
cellular
receptor
antivir
activ
might
therefor
consequ
mechan
mab
design
belong
group
mab
bind
upstream
rbd
thu
author
gener
pseudoviru
system
contain
hiv
backbon
express
sarscov
protein
hiv
use
examin
abil
mab
inhibit
viral
entri
pseudoviru
bound
cell
transient
transfect
human
receptor
h
allow
viral
attach
bind
entri
cell
treat
increas
concentr
mab
incub
luciferas
activ
detect
way
coughlin
et
al
demonstr
mab
inhibit
postbind
step
viral
entri
postbind
inhibit
significantli
greater
indic
direct
preincub
pseudoviru
mab
ad
target
cell
therefor
mab
might
prevent
conform
chang
necessari
protein
cleavag
cathepsin
studi
author
test
efficaci
combin
mab
inhibit
sarscov
entri
combin
mab
differ
rbdspecif
mab
group
includ
test
neutral
via
hiv
pseudotyp
viru
assay
result
reveal
mab
combin
demon
strate
signific
increas
inhibit
similar
increas
protect
detect
combin
mab
neutral
live
sarscov
urbani
infect
vero
cell
result
suggest
combin
antibodi
contain
distinct
epitop
neutral
viru
differ
mechan
may
result
greater
inhibit
viru
infect
escap
mutant
gener
presenc
mab
studi
coughlin
et
al
author
test
abil
mab
yield
escap
mutant
preincub
individu
mab
sarscov
urbani
incub
mixtur
vero
cell
nine
passag
viru
supernat
found
escap
mutant
emerg
presenc
nine
mab
differ
passag
viru
cultur
suggest
mab
possess
differ
abil
select
escap
mutant
use
individu
howev
escap
mutant
virus
could
effect
neutral
mixtur
mab
consist
indic
cocktail
mab
may
effect
suppress
escap
mutant
result
consist
previou
report
ter
meulen
et
al
demonstr
mixtur
two
noncompet
human
mab
recogn
differ
epitop
rbd
may
neutral
sarscov
infect
synergist
fashion
potenti
control
immun
escap
extend
breadth
protect
passiv
immunotherapi
driven
neutral
human
mab
could
effect
candid
prophylaxi
treatment
sarscov
infect
neutral
antibodi
respons
sarscov
protein
could
broadli
elicit
viru
infect
demonstr
longlast
immun
sera
recov
sar
patient
human
mab
sarscov
evalu
anim
model
demon
strate
efficaci
human
mab
exampl
may
larg
reduc
viral
replic
given
prophylaxi
mice
dose
therapeut
achiev
human
accord
robert
et
al
therapi
neutral
human
mab
sarscov
reduc
diseas
sever
viral
burden
golden
syrian
hamster
fact
suggest
neutral
mab
may
use
import
emerg
prophylaxi
help
rapidli
clear
viru
thu
provid
immedi
protect
human
popul
event
sar
outbreak
previous
mention
mechan
mab
antivir
agent
may
vari
depend
target
epitop
region
mab
target
epitop
within
rbd
report
coughlin
et
al
other
interfer
virusreceptor
inter
action
block
attach
viru
target
cell
thu
provid
protect
sarscov
replic
mab
test
coughlin
et
al
studi
target
domain
upstream
rbd
inhibit
viral
entri
postbind
event
sinc
human
mab
inhibit
sarscov
infect
differ
mechan
combin
mab
variou
mechan
inhibit
target
multipl
antigen
epitop
may
induc
addit
synergist
effect
larg
reduc
possibl
neutral
escap
mutant
gener
studi
rockx
et
al
indic
cocktail
three
mab
target
distinct
epitop
complet
protect
age
mice
weight
loss
viru
replic
lung
follow
lethal
challeng
live
sarscov
minim
like
gener
escap
mutant
enhanc
protect
effect
combin
mab
recogn
distinct
neutral
epitop
confirm
current
studi
overal
stand
mechan
action
lie
antivir
activ
mab
instrument
design
develop
novel
therapeut
treatment
sarscov
infect
conclus
immunotherapi
human
protect
antibodi
shown
prophylact
therapeut
potenti
sarscov
infect
anim
model
thu
provid
import
basi
clinic
trial
mab
human
popul
use
sarscovspecif
human
mab
prophylaxi
may
provid
safe
feasibl
efficaci
way
prevent
viru
infect
thu
serv
altern
signific
intervent
vaccin
howev
caution
taken
use
neutral
human
mab
immunoprophylaxi
strategi
genotyp
surveil
sarscovlik
genotyp
known
anim
reservoir
might
requir
note
passiv
transfer
antibodi
may
less
effici
protect
immunosenesc
popul
young
popul
expect
even
effect
neutral
mab
target
multipl
epitop
sarscov
contain
differ
mechan
could
develop
test
prevent
sar
infect
treatment
sar
patient
object
studi
n
understand
mechan
human
monoclon
antibodi
mab
recogn
epitop
within
upstream
receptorbind
domain
inhibit
sarscoronaviru
cov
replic
detect
efficaci
antibodi
combin
suppress
viru
escap
mutant
neutral
viru
infect
n
receptorbind
inhibit
assay
vero
cell
natur
express
receptor
angiotensinconvert
enzym
ace
detect
inhibit
mab
bind
protein
receptor
n
pseudotyp
sarscov
neutral
assay
base
hiv
backbon
sarscov
protein
detect
postbind
inhibit
mab
test
efficaci
combin
mab
inhibit
sarscov
entri
n
neutral
assay
base
live
sarscov
urbani
detect
protect
mab
combin
sarscov
urbani
detect
mab
mixtur
suppress
escap
mutant
virus
virusinfect
vero
cell
n
mixtur
contain
mab
recogn
distinct
region
target
multipl
step
viral
entri
effect
individu
mab
use
alon
neutral
sarscov
infect
suppress
mutant
viru
gener
thu
serv
potenti
passiv
immunotherapi
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
includ
employ
consult
honoraria
stock
ownership
option
expert
testimoni
grant
patent
receiv
pend
royalti
write
assist
util
product
manuscript
